Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation...

-Flamingo is developing two RNA therapies for cancer: danvatirsen, an antisense oligonucleotide in Phase 2 PEMDA-HN study, and FLM-7523, a MALAT1 inhibitor approaching Phase 1- LEUVEN, Belgium and...

Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne...

Nota AI, a leader in hardware-aware AI optimization and on-device AI solutions, has taken a significant step toward establishing its presence in the Middle East by signing a Memorandum of...

According to the news released by the Ministry of Industry and Information Technology in September this year, China has maintained the world's first shipbuilding completion volume, new orders, and...